← FDA DRUG APPROVALS
FDA ANDA · ANDA074951
BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE
Sponsor: STEVENS J
APPLICATION
ANDA074951
TYPE
ANDA
ORIGINAL APPROVAL
1998-08-31
LATEST ACTION
2026-06-18
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription
Products
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATEPrescription
ASPIRIN 325MG, BUTALBITAL 50MG, CAFFEINE 40MG, CODEINE PHOSPHATE 30MG · CAPSULE · ORAL
Approval history
2026-06-18REMS · Supplement 13AP
2025-12-22Labeling · Supplement 11 · standardAP
2024-11-21Labeling · Supplement 10 · standardAP
2024-10-31REMS · Supplement 9AP
2024-10-09Labeling · Supplement 8 · standardAP
2023-12-15Labeling · Supplement 7 · standardAP
2023-12-11Labeling · Supplement 5 · standardAP
2018-09-18REMS · Supplement 4AP
2007-11-09Labeling · Supplement 2AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.